ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Fei Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7434-7339; OpenAlex author ID A5100412154. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 13

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Chunlin Ge · 1 shared paper, 2024 · strength 0.36
- Paper Prevalence and Impact of Frailty in Pancreatic Cancer: A Systematic Review and Meta-Analysis Based on 35,191 Patients. DOI 10.1245/s10434-023-14426-y ↗
Ting Deng · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Zhi‐Qiang Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
De‐Shen Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Le Zhang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Feng‐Hua Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Rui‐Hua Xu · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Wei Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Yuhong Li · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Yi Ba · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Chen Liang · 1 shared paper, 2015 · strength 0.06
- Paper miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer… DOI 10.1007/s13277-015-3679-5 ↗
Hongyu Li · 1 shared paper, 2015 · strength 0.06
- Paper miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer… DOI 10.1007/s13277-015-3679-5 ↗
Ying-Yi Li · 1 shared paper, 2015 · strength 0.06
- Paper miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer… DOI 10.1007/s13277-015-3679-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.